Trends in the Utilization of Herbal and Dietary Supplements in Patients with Chronic Liver Disease During the SARS-CoV2 Pandemic

Avleen Kaur; Ahyoung Kim; Lisa R Yanek; Yisi Liu; Xueting Tao; Anna Peeler; Douglas Mogul; James Peter Adam Hamilton; Gerard E Mullin

Trends in the Utilization of Herbal and Dietary Supplements in Patients with Chronic Liver Disease During the SARS-CoV2 Pandemic

Integr Med (Encinitas). 2023 Nov;22(5):14-17.

Authors

Avleen Kaur¹, Ahyoung Kim², Lisa R Yanek³, Yisi Liu³, Xueting Tao³, Anna Peeler², Douglas Mogul², James Peter Adam Hamilton², Gerard E Mullin²

Affiliations

¹ Maimonides Medical Center, Brooklyn, New York, USA.
² Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
³ Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Biostatistics, Epidemiology, and Data Management (BEAD) Core, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

PMID: 38144166
PMCID: PMC10734968 (available on 2024-11-01)

Abstract

Background: We studied the pattern of herbal and dietary supplement (HDS) use in patients with chronic liver disease (CLD) during the first year of the COVID-19 pandemic.

Methods: A questionnaire/survey was sent to hepatology patients with CLD under the care of hepatologists at Johns Hopkins University School of Medicine.

Results: The 5 most taken dietary supplements during the pandemic included vitamin B12 (27.7%), vitamin C (32.4%), vitamin D (54.6%), zinc (25.4%) and green tea extract (20.8%). Most participants (82.3%) did not discuss their HDS use with their hepatology providers.

Conclusions: Healthcare providers should be mindful of potential HDS use in patients with CLD.

Abstract

Grants and funding